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Abstract
Activation of CD4+ T cells requires the recognition of peptides that are presented by HLA
class II molecules and can be assessed experimentally using the ELISpot assay. However,
even given an individual’s HLA class II genotype, identifying which class II molecule is
responsible for a positive ELISpot response to a given peptide is not trivial. The two main
difficulties are the number of HLA class II molecules that can potentially be formed in a sin-
gle individual (3–14) and the lack of clear peptide binding motifs for class II molecules.
Here, we present a Bayesian framework to interpret ELISpot data (BIITE: Bayesian Immu-
nogenicity Inference Tool for ELISpot); specifically BIITE identifies which HLA-II:peptide
combination(s) are immunogenic based on cohort ELISpot data. We apply BIITE to two ELI-
Spot datasets and explore the expected performance using simulations. We show this
method can reach high accuracies, depending on the cohort size and the success rate of
the ELISpot assay within the cohort.
Author Summary
When studying the host immune response, a central question is: “which peptides elicit
CD4+ T cell responses?” ELISpot assays are used to assess if subjects have responded to a
given peptide. However, to determine which of the HLA-II molecules coded by the host
HLA genotype is responsible for the reaction requires additional analysis. We present a
Bayesian approach to solve this problem and have implemented it for use with the statisti-
cal language R under the BIITE moniker. Importantly, the aim of BIITE is to interpret
experimental data, not to make in silico predictions. The method considers the immunoge-
nicity of all HLA (in a cohort of patients) with respect to a given peptide simultaneously,
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in order to deal with linkage disequilibrium between genes of the HLA locus. Furthermore,
users can enter additional information they might have (from literature or other experi-
ments) in the form of prior information. The method is not exclusive to the HLA genes
and can be used to attribute positive binary outcomes to any multi-allelic set of genes.
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Introduction
Adaptive immunity relies on the recognition of non-self peptides by T cell receptors to mount
an effective response against an infection. Both self and non-self peptides are presented on the
cell surface by human leucocyte antigen complex (HLA) molecules using two pathways: the
HLA class I pathway presents cytosolic peptides on HLA class I molecules to CD8+ T cells,
while the HLA class II pathway presents peptides of proteins that have been internalized by
antigen presenting cells (APCs) to CD4+ T cells.
Identifying which peptide:HLA (pHLA) complexes give rise to an immune response in any
infectious, autoimmune, allergic or oncogenic disease is paramount to understanding host
defence and pathogenesis and informing epitope vaccine design. Furthermore, the ability to
define the specific pHLA complexes dominating a given response is central to both the theoreti-
cal understanding of HLA-disease associations and to the practicalities of designing experiments
that use pHLA tetramers to enumerate and characterise specific T cells. Only a small proportion
of HLA-binding peptides are able to elicit a T cell response in the context of a given HLA class I
[1] or class II molecule; identifying which pHLA complexes are immunogenic is not trivial.
The most widely used experimental method for investigating immunogenicity in humans is
the ELISpot assay [2]. Interpreting ELISpot responses of CD8+ T cells is relatively straightfor-
ward. Given an individual’s HLA class I genotype there are a limited number of HLA-I mole-
cules that could be present (a maximum of 6); this together with the highly specific nature of
the HLA class I peptide binding register means that identifying which HLA molecule is respon-
sible for a positive response in a given individual to a certain peptide is usually unambiguous.
Here we focus on the more demanding problem of defining immunogenic pHLA-II com-
plexes. That is, having established that an individual of known HLA class II genotype gives a
positive CD4+ T cell ELISpot response to a given peptide, how could one infer which of the
class II molecules was responsible for eliciting this response? Multiple factors complicate this
analysis. Firstly, HLA-II molecules are heterodimers whose alpha and beta chains are encoded
at separate genetic loci. Given their high polymorphism (the exception being the locus encod-
ing the DR alpha chain) and the fact that their products might be paired either in cis or in
trans, the number of expressed DP and DQmolecules in heterozygotes is theoretically doubled
[3–6]. Furthermore, the DR alpha chain can be paired with the DQ beta chains [7]. Secondly,
the DR beta chain can be sourced from between 2 to 4 loci depending on the subject. All
humans possess two copies of the DRB1 locus. These can be complemented by a maximum of
two of DRB3, DRB4 or DRB5 (one per chromosome). Consequently a maximally heterozygous
individual may have 14 distinct HLA class II molecules. Thirdly, expression levels seem to dif-
fer [8] between different chains, leading to differential presentation of HLA-II molecules on
the cell surface. Fourthly, (as for the class I genes), the genes of the HLA-II locus are in strong
Bayesian Immunogenicity Inference Tool for ELISpot
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004796 March 8, 2016 2 / 18
Discovery Program and funded by the National
Institutes of Health (NIH) Contract number:
HHSN272200900046C (Boyton and Altmann). KJQ
was supported by an MRC PhD studentship and CJR
was supported by the Welton Foundation (P14475,
Boyton). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
linkage disequilibrium, complicating the attribution of T cell responses to specific HLA-II loci.
Lastly, the class II peptide binding grove is open at both ends and so it can accommodate pep-
tides of variable length. This means that several amino acids in a given peptide could be anchor
residues, complicating the in silico scanning of peptides for binding motifs. Together these fac-
tors mean that identifying which of an individual’s 3–14 possible HLA class II molecules is
responsible for eliciting a positive CD4+ T cell response is problematic.
Historically, this problem has been addressed by cloning T cells and dissecting responses
functionally, for example with HLA transfectant APC panels. However, this is intractable for
high-throughput epitope mapping studies. While methods exist for predicting binding of pep-
tides to HLA class II molecules, for example NETMHCIIpan [9], our aim is different in two
important respects. Firstly, we are seeking a method to interpret experimental data rather than
to make in silico predictions; secondly, we aim to infer immunogenicity rather than peptide
binding. Paul et al. have recently described the RATE method [10] which addresses the same
question. Their method calculates the relative frequency (RF) of positive CD4+ T cell ELISpot
outcomes from multiple individuals in the HLA+ and HLA- groups in order to discover immu-
nogenic pHLA combinations. In contrast, we propose a Bayesian framework to determine the
immunogenicity of peptide:HLA-II complexes for a given peptide, which allows us to consider
all HLAs simultaneously. We have implemented this in the R package BIITE (Bayesian Immu-
nogenicity Inference Tool for ELISpot).
Methods
Model
We will use the abbreviation HLA to denote HLA-II, but the same approach could be used to
determine HLA class I peptides from CD8+ T cell ELISpot data. Assume we have ELISpot data
D for a single peptide in a cohort of N individuals, in which a total ofmHLAmolecules are
present. We wish to obtain the peptide:HLA immunogenicity, E, for each of themHLAs as a
number between 0 and 1; this is approximately the probability that a pHLA combination
results in a positive ELISpot in a randomly chosen individual (with the relevant HLA allele)
and would be exact if each subject presented exactly one HLA. Hence, the hypothesis space we
will explore is [0, 1]m. Bayes’ theorem (see S1 Text for more information) states that the poste-
rior likelihood P(H|D) for a hypothesis H = (E1,E2,. . .,Em) 2 [0,1]m is proportional to the prod-
uct of the prior P(H) and the likelihood P(D|H):
PðHjDÞ / PðDjHÞPðHÞ:
Likelihood
We define the likelihood P(D|H) multiplicatively:
PðDjHÞ ¼
YN
i¼1
PðDijHÞ;
where Di denotes the data for one individual and P(Di|H) is defined as
PðDijHÞ ¼
Ym
j¼1
ð1 EjÞnij if subject i has a negative ELISpot;
1
Ym
j¼1
ð1 EjÞnij if subject i has a positive ELISpot:
8>><
>>:
ð1Þ
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Here, nij is the copy number of HLA allele j in subject i. The logic behind this formula is
explained in more detail in S1 Text.
Prior
The algorithm allows for the inclusion of pre-existing knowledge or beliefs. These could be
results from previous experimental assays or from prediction algorithms. When no prior
knowledge is given, the prior is the uniform distribution on [0,1]m. When prior knowledge is
available, we assume it is on an HLA molecule-by-molecule basis:
PðH ¼ ðE1; E2; . . . ; EmÞÞ ¼
Ym
j¼1
PðEjÞ:
In our analysis, we used prior data from NetMHCIIPan [9]. NetMHCIIPan was used to pre-
dict the binding of peptide:HLA combinations with a cut-off of IC = 500nM. The combinations
below this threshold were assigned a Beta prior with mode 0.35 and SD 0.2; combinations
above this threshold were assigned a Beta prior with mode 0.001 and SD 0.15 (see S1 Fig).
Implementation
In order to find the posterior density P(H|D), we implemented the Metropolis-Hastings algo-
rithm [11], which is explained in more detail in S1 Text, to construct Markov chains of length
100,000, as these were found to return the same marginal distributions as chains of length
10^6. The model was implemented in R version 3.1 [12]. The graphical output was generated
with the R package ggplot2 [13]. The code is available on http://github.com/liesb/BIITE as an R
package. It can be installed using the R library devtools. In R, use the command install.pack-
ages("devtools") to install devtools. Then, to install BIITE, load devtools using the command
library(devtools); next, use devtools::install_github("liesb/BIITE") to retrieve BIITE from its
github repository. To load the package, use library(BIITE).
Input format
An example input file can be found in S4 Table. Each row in the file represents a subject. There
should be a column for each HLA in the population, which contains the subjects’ copy number
of that gene. For each peptide that is tested, there is a column, containing a logical value: TRUE
if the subject delivered a positive ELISpot for the peptide, otherwise FALSE. The order of the
columns does not matter, although preferably the ELISpots columns and the HLA columns
form one block each. The HLA data can be entered in two-digit or four-digit format or a mix-
ture of the two (see the example in S1 Table): most HLAs are defined on the two-digit level, but
DRB115 has been split intoDRB115:01 andDRB115:02). Since ‘’ is a special character in the
R language, it should not be used in the column names and can be replaced by an underscore.
Interpretation of the posterior
In order to estimate the immunogenicity of each peptide:HLA combination, we consider the
marginal distributions P(. . .,Ej,. . .|D) for each of the HLA molecules in the population. If the
data contain little information about the immunogenicity of a pHLA combination (e.g. the
HLA molecule is present only at very low frequencies in the population), then this marginal
posterior distribution will not differ very much from the prior it was assigned.
If a pHLA combination has a relatively flat posterior distribution then its immunogenicity
cannot be reliably determined; this will occur when limited information about the pHLA is
contained in the data. We eliminate these unreliable combinations by only considering pHLA
Bayesian Immunogenicity Inference Tool for ELISpot
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combinations which differ from the uniform distribution. We quantify the difference between
the posterior and the uniform using the Kullback-Leibler divergence DKL(P(Ej|D)||Unif(0,1)).
If this difference is smaller than DKL(Beta(2,1)||Unif(0,1)) we say there is insufficient informa-
tion to determine the immunogenicity. We have chosen the threshold to be determined by the
Beta(2,1) distribution, which naturally arises as the posterior distribution of the parameter of
the binomial distribution after one (positive or negative) observation, when assuming a uni-
form prior. In other words, if we want to know what the probability p is of a coin landing heads
in a toss, and we are only allowed one experiment with no prior information, Beta(2,1) (or Beta
(2,1)) is the best description of p. Hence, requiring that the Kullback-Leibler divergence passes
the aforementioned threshold, is asking that the posterior contains more information that we
would get from a single coin toss. This threshold is arbitrary and can be adjusted by the user.
To obtain a single estimate for Ej, we propose using the mode of the marginal posterior dis-
tribution, but other summary statistics could be considered. In our analyses, using either the
mean or median of the marginal posterior distribution yielded very similar results. These three
summary statistics are all provided in the output of the algorithm (see S8 Table for an example
where we have retained only the mode). Our interest lies in determining, for a given peptide,
which HLA molecules were responsible for the observed positive ELISpot assays in the dataset,
i.e., which HLA has the highest explanatory power. This can be done as follows. Based on the
output file, we can rank the HLAs from highest posterior mode to lowest posterior mode; the
HLAs ranked highest are the ones identified by BIITE to be the most immunogenic. Next, we
turn to the subject data and determine which of their HLAs has the highest rank. For a subject
with a positive ELISpot, this one ‘highest ranked HLA’ is considered to be the HLA responsible
for the positive ELISpot result. To check whether a single HLA has high explanatory power, we
determine how many subjects with a positive ELISpot carry that HLA, and in how many of
these subjects the HLA is the highest ranked HLA.
Worked example
To illustrate the application of the method we have created a worked example. The input file is
provided in S4 Table, the corresponding output file (for pep_1) in S8 Table. The HLAs are
ranked from high to low (‘Posterior mode’ column). For each HLA, we count how many sub-
jects carry the HLA and have produced a positive ELISpot (‘# Carriers with positive ELISpot’).
For example, of the 73 carriers of DQB03, 67 had a positive ELISpot. Since DQB03 is also the
highest ranked HLA overall, all of these 67 positive ELISpots are ‘explained’ by DQB03. For
the second-highest ranked HLA, DRB114, 25 of 28 subjects had a positive ELISpot. Fourteen
of those 25 are explained by DRB114 (the other 11 DRB114 carriers with a positive ELISpot
also carry the higher ranked DQB03, which ‘explains’ their positive ELISpot). In contrast, the
lowest-ranked HLA, DQB02, has 54 carriers that produced a positive ELISpot, but none of
these positive results are explained by DQB02.
Validation on a Burkholderia Pseudomallei dataset
The bacterium Burkholderia Pseudomallei is the causative agent of melioidosis. PBMCs from a
small cohort (N = 38) of exposed sero-positive blood donors were used to test 17 overlapping
20-mers of the alkyl hydroperoxide reductase protein (AhpC, BPSL2096) by IFNγ ELISpot
assay [14]. Results that were 2 standard deviations (SD) above the mean of medium only con-
trol were considered positive.
Each subject was HLA genotyped at theHLA-DRB1 and HLA-DQB1 loci. The observed
alleles and their frequencies in the cohort are listed in S1 Table.
Bayesian Immunogenicity Inference Tool for ELISpot
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We applied the algorithm to each of the 17 peptides separately, both with and without the
inclusion of prior data.
We used two datasets for validation. In the first dataset, immunogenicity of pHLA com-
plexes for 6 HLAs (DRB101, DRB104, DRB115:01, DRB115:02, DQB106, DQB108) was
determined using transgenic mouse models that express a single (human) HLA-II molecule
(and no mouse MHC class II) and were challenged with the 17 different peptides in turn; IFNγ
ELISpot was then used to determine whether peptides were immunogenic (number of SFCs
larger than mean of SFCs numbers in medium-only + 2SD) [14]. The second dataset consisted
of relative peptide binding affinities for all 17 overlapping 20-mers of the protein with respect
to 10 HLA-II molecules; this was evaluated with competitive ELISA using an automated work-
station. A peptide was considered to be binding to the HLA molecule when the relative binding
affinity was less than 100 [14].
The immunogenicity of each pHLA combination was calculated as the mode of the mar-
ginal posterior distribution. We constructed ROC curves to compare these values to the pHLA
binding data and transgenic immunogenicity data.
Validation on a Pseudomonas Aeruginosa dataset
The bacterium Pseudomonas Aeruginosa (PA) is an environmental organism that can cause
infection in damaged lung or the immune compromised host. PBMCs from a small cohort
(N = 58) of patients with a chronic lung disease associated with recurrent lung infection and
progressive lung damage, called bronchiectasis, were used to test 34 overlapping 20-mers of the
OprF protein using IFNγ ELISpot assays [15]. We used a cut-off of 2SD above the mean of
medium only control to decide whether a particular ELISpot result for an individual was posi-
tive or negative.
Analogously to the Burkholderia dataset, we had access to a immunogenicity data derived
from transgenic mouse models and binding data from peptide-binding assays [15]. Transgenic
mouse models were available for DRB101, DRB104 and DRB115; binding data was available
for 7HLA-DRB1 alleles.
Each subject was HLA-typed at the HLA-DRB1 and HLA-DQB1 loci. The observed alleles
and their frequencies in the cohort are listed in S2 Table. Each subject is classified into one of
two groups, based on the results of sputum microscopy and culture by standard microbiolog-
ical techniques. Individuals in group 1 were never sputum culture positive for PA, while indi-
viduals in group 2 were sometimes or frequently sputum culture positive for PA over a period
of 6 months.
We first applied the algorithm to each of the 34 peptides separately, both with and without
the inclusion of prior data, including all subjects. Next, we applied the algorithm to each of the
two groups (as described above) separately.
Validation on synthetic datasets
In order to assess the validity of the method and the effect of sample size on the outcomes of
the algorithm, we resampled (with replacement) HLA class II haplotypes from the Burkhol-
deria dataset (n = 10, 30, 50, 70, 100, 150, 200). We randomly assigned each peptide:HLA mole-
cule an immunogenicity value Ej2[0,0.55]; whether a peptide:HLA combination was
considered immunogenic was decided by a cut-off on Ej; we considered a range of different
cut-offs (0.1, 0.2, 0.3, 0.4, 0.5). We then simulated ELISpot data in the following way: for each
subject, the probability of having a positive ELISpot was calculated using eq (1) above, whether
the individual had a positive or negative ELISpot was then decided by drawing a random num-
ber from the unit interval and comparing it to this probability; if the random number was
Bayesian Immunogenicity Inference Tool for ELISpot
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above the computed probability then the individual had a negative ELISpot, if it was below
they had a positive ELISpot. We constructed ROC curves and calculated the AUC for the dif-
ferent cut-offs listed above.
Comparison to RATE
Recently, Paul et al [10] have proposed a novel algorithm “RATE” to determine immunogenic
peptide:HLA complexes from ELISpot data. We applied the RATE tool to both the Burkhol-
deria and the Pseudomonas dataset. RATE returns two reports: a concise one, which contains
the pHLA combinations who have a positive ELISpot relative frequency (RF) greater than two;
and a complete report which ranks all peptide:HLA combinations in the population. We calcu-
lated the AUC for each dataset based on the RF of all the pHLA complexes whose posterior dis-
tributions passed the Beta(1,2) cut-off criterion described above.
Validation on an HIV-1 dataset (HLA class I restricted CD8+ T cells)
While BIITE was designed to address the issue of elucidating peptide:HLA immunogenicity for
class II HLA, we hypothesized that it could solve a larger class of problems (see Discussion). To
explore the performance of BIITE on different datasets, we downloaded patient data and CD8+
T cell ELISpot outcomes for a range of HIV-1 peptides from [16]. We used 2-digit level typing
for all HLAs, except for HLA-B15 (where we used B15:03 and B15:10 if this subtyping was
provided, and B15 else), HLA-B58 (B58:01 and B58:02) and HLA-A30 (A30:01 and
A30:02). For other HLA alleles, we either lacked sufficient HLA-typing on the 4-digit level, or
there was one dominant 4-digit allele; see S5 Table for an overview. We applied the algorithm
to the 32 peptides used for validation in [10] to sample the posterior probability distribution
on the hypothesis space (sample size 250,000). The output was interpreted as described above
and peptide:HLA combinations that were predicted to be immunogenic were matched against
entries in the LANL A-list of HIV-1 epitopes and the general LANL database.
Results
We designed and implemented a Bayesian framework, BIITE, to determine peptide:HLA
immunogenicity from ELISpot data; Fig 1 outlines the algorithm. The algorithm determines
the probability density function of the immunogenicity. The immunogenicity of a pHLA com-
bination is the approximate probability that the peptide results in a positive ELISpot in a ran-
domly chosen individual with the relevant HLA allele (this value would be exact if each subject
expressed only one HLA). Strictly necessary inputs are the ELISpot experiment outcomes for
each subject, together with their genotype for the loci of interest. Optionally, the user can also
provide prior information to the algorithm; this is done on an HLA molecule-per-molecule
basis. The output of the algorithm is a sample of the posterior distribution P(H|D), which we
visualize by plotting the marginal posterior density for each peptide:HLA combination. This
can be interpreted as the probability density function of the immunogenicity.
Validation on Burkholderia dataset
In order to test the BIITE algorithm, we used CD4+ T cell ELISpot data from a small cohort of
exposed sero-positive individuals (N = 38). All overlapping 20-mer peptides from the
BPSL2096 protein were tested (see Methods).
In Fig 2A, we present the marginal posterior distributions of the immunogenicity (solid
lines) for all HLA molecules in combination with a single, representative peptide (BPSL2096,
1–20), calculated using a uniform prior. Especially for rare alleles (see S1 Table), the
Bayesian Immunogenicity Inference Tool for ELISpot
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distributions are rather flat and uninformative. We also show the marginal posterior distribu-
tions, now assuming a non-uniform prior as described above (Fig 2A, dashed lines). The poste-
rior distributions are now markedly more pronounced. This is of course driven by the prior
assumptions, especially for the rare alleles. Nevertheless, there are divergences between the pos-
terior and the prior. For example, for the representative peptide shown in Fig 2A both
DRB101 (2 carriers) and DRB108 (4 carriers, one of which is homozygous), were assigned a
positive prior (i.e. both were predicted to bind the peptide), yet they have different posteriors,
reflecting the fact that both DRB101 carriers had positive ELISpot results, whilst there were
two DRB108 carriers with a negative ELISpot.
We compared the posterior marginal distributions to the transgenic mouse model data (6
data points for each of the 17 peptides). To do so, one needs to collapse the posterior distribu-
tion to a decision: is the pHLA combination immunogenic or not, according to the model? For
this analysis, we used the mode of the marginal posterior distribution as a summary statistic,
and the decision rule was based on the mode being above a certain threshold. We then con-
structed a ROC curve by varying this threshold (Fig 2B). To interpret the strength of an
Fig 1. Outline of the algorithm.We aim to describe the immunogenicity of a peptide:HLA combination as a
number between 0 and 1. For each subject, the outcome of the ELISpot assay is known, together with a list of
their HLA alleles. The user can add prior knowledge in the form of a prior distribution. In the example, the prior
knowledge describes the belief that HLA class II allele A is not immunogenetic in combination with the
peptide, while HLA class-II allele B is. The output of the algorithm consists of posterior marginal distributions
of the values Ej. In the example, it is found that allele A is more immunogenic that allele B in combination with
the peptide.
doi:10.1371/journal.pcbi.1004796.g001
Bayesian Immunogenicity Inference Tool for ELISpot
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Fig 2. Application of the algorithm to the Burkholderia data set, with (dashed lines) and without (solid
lines) inclusion of prior information. (A) Marginal posteriors of the peptide:HLA immunogenicities for
BPSL2096 1–20 (Allele count in the cohort in brackets). (B) ROC curves were generated by comparing the
mode of the posterior distributions against the transgenic mouse data set. For these curves, we have
removed all posterior distributions whose Kullback-Leibler divergence with respect to the uniform distribution
on the unit interval was smaller than that of the Beta(1,2) distribution.
doi:10.1371/journal.pcbi.1004796.g002
Bayesian Immunogenicity Inference Tool for ELISpot
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algorithm, one compares it to the diagonal; this is the theoretical ROC curve for a random deci-
sion rule. The observed AUC is 71.3% when we use a uniform prior, and 65.4% when using a
prior based on the predictions of NetMHCIIPan.
Validation on Pseudomonas dataset
We performed an additional analysis on a Pseudomonas dataset, comprised of N = 58 subjects.
The AUCs we found were 68.8% (without predictive prior), 79.3% (with predictive prior) (see
Fig 3).
The subjects in the Pseudomonas study were divided into two groups, based on the number
of positive sputum tests they had delivered. In this study, individuals with a high number of
sputum cultures positive for PA had a lower immune responsiveness (lower number of peptide
that elicited a T cell response) compared to individuals that were never sputum culture positive
for PA, indicating that there were two different clinical groups with different peptide immuno-
genicities. Hence, we applied our algorithm to each of the groups separately, and predicted that
the algorithm would perform poorly on the data from group 2 (who had very low response
rates in their ELISpot assays). Indeed, for group 2 (subjects with at least one positive sputum
sample), we found that BIITE was unsuccessful at resolving the HLA:epitope combinations
found to be immunogenic in transgenic mice (AUC: 32% without prior; 69% with prior); this
apparently low performance is not unexpected as these combinations were not immunogenic
in humans. For group 1, BIITE reached AUCs of 69% (without prior) and 73% (with prior).
Determinants of performance
Cohort size. To test the effect of the sample size of the ELISpot dataset, we modelled 17 in
silico peptides based on a population of 200 subjects whose HLA class II haplotype was drawn
(with replacement) from the Burkholderia cohort. We set peptide immunogenicity such that the
odds ratio of having a positive ELISpot was similar to that in the Burkholderia dataset (S2 Fig).
Fig 3. ROC curves for the analysis of the Pseudomonas data set, with (dashed line) and without (solid
line) inclusion of a predictive prior.
doi:10.1371/journal.pcbi.1004796.g003
Bayesian Immunogenicity Inference Tool for ELISpot
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We then applied the algorithm to this new population and to subpopulations thereof. To vali-
date the performance of the model, one needs to first decide which of the pHLA combinations
are considered immunogenic. We did so by choosing a cut-off on the immunogenicity value Ej
of each simulated pHLA combination; different cut-offs were considered (see Methods). For
each of these cut-offs, we construct ROC curves and compute the AUC. Fig 4A shows the values
of the AUC as a function of the cut-off on Ej and the population size. Unsurprisingly, perfor-
mance of the model as measured by AUC increases with population size. Optimal AUCs were
reached when the cut-off was taken at 0.4. Fig 4B shows the ROC curves associated with this
Fig 4. Simulated data based on the Burkholderia dataset. (A) Evolution of the AUC with sample size, for
different cut-offs on what is considered to be an immunogenic response. (B) ROC curves for different
population sizes, based on a cut-off for immunogenicity of 0.4.
doi:10.1371/journal.pcbi.1004796.g004
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cut-off. It is interesting to note that in our original Burkholderia dataset, where sample size was
38, we reached an AUC of 71%, which is comparable to the results found for sample sizes 30
and 50 here (72% and 75% respectively).
Crossreactivity. We also investigated how the crossreactivity of the peptide affected the
performance of the BIITE algorithm. Intuitively, we expect that is it easier to determine the
HLA ligands of a peptide that is poorly reactive (ie, not many positive ELISpots). This is easiest
to understand in the extreme case of immunogenicity values Ej2{0,1}: each negative ELISpot
would indicate that none of the HLAs of the subject is immunogenic; while a positive ELISpot
result only informs us that (at least) one of the subject’s HLAs is immunogenic in combination
with the peptide. In this extreme case, when all the subjects produce positive ELISpots, it is
impossible to attribute these positive outcomes to any HLA.
To confirm the effect of the number of positive ELISpots, we ordered the peptides in the
Burkholderia dataset based on the success rate (i.e. how many positive results they produced)
in the ELISpot assay in our cohort, and grouped the peptides accordingly (see S3A Fig). We can
now compute the performance of the algorithm on each of these subsets. Following the reason-
ing above, we predict that the AUC will be negatively correlated with the success rate (S3B Fig);
this is indeed the case (S3C Fig). Note that if very few positive ELISpots are observed, the algo-
rithm might also underperform: in the extreme case of observing one positive ELISpot, there
are many candidate HLAs in that subject that could be presenting the peptide. If these HLA
molecules are present at similar frequencies in the cohort, the algorithm is unable to distinguish
which of the possible pHLA complexes is responsible for triggering the CD4+ T cell response.
Comparison to RATE. To our knowledge, there exists only one other algorithm, RATE
[10], which uses ELISpot data to infer immunogenicity of pHLA complexes. In contrast with
our Bayesian approach (which allows for inclusion of prior data and considers all HLAs simul-
taneously), the RATE software uses the frequentist exact Fisher test to compare the odds ratios
(and the relative frequency, RF) of having a positive ELISpot in the HLA+ and HLA- groups.
We first applied RATE to the Burkholderia dataset; it returned two potential pHLA restrictions
with high RF: peptide5:DRB101 and peptide5:DQB104. Transgenic mouse data is only avail-
able for the first combination and was negative. Both combinations have a high (>0.9) poste-
rior mode in our analysis, but lack power (Kullback-Leibler divergence below Beta cut-off) as
both occur only twice in our cohort. The overall AUC based on RF was 53.6% (compared to
71.3% for BIITE). When applied to the Pseudomonas dataset, RATE returned 54 pHLA combi-
nations with RF greater than 2; unfortunately, there is no transgenic mouse data available for
any of these combinations. Based on the pHLA combinations that were tested in transgenic
mice, we found that RATE reached an AUC of 49% (compared to 68.8% for BIITE). In the two
subcohorts of the Pseudomonas dataset, RATE reached AUCs of 55% in group 1 (compared to
69% or 73% for BIITE, depending on the inclusion of a prior based on binding predictions, see
above) and 29% in group 2 (compared to 32% or 69% for BIITE).
Comparison to NetMHCIIPan. Immunogenicity and binding affinity are correlated and
so it is also instructive to compare our algorithm with the best available affinity predictor, namely
NetMHCIIPan [9,17]. We used NetMHCIIPan to construct ROC curves, based on the binding
threshold, for the pHLA combinations we had previously considered. For the Burkholderia data,
this yielded an AUC of 67.7% (compared to 71.3% from our analysis). Since we also obtained
experimental binding data for several pHLA combinations from the Burkholderia dataset, we
were interested in the cases where the binding assay and transgenic mouse models gave discor-
dant results. These can be divided in two groups: one where the transgenic mouse model suggests
immunogenicity, while the binding assay indicates there is no stable binding, and vice versa. In
the first group there were five such observations. Only one of these (20%) is predicted to bind by
NetMHCIIPan. Our algorithm is powered to determine 3 of the pHLA combinations of which
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two (66%) are correctly identified as immunogenic (S3A Table). The second group, which con-
tains pHLA combinations which reach stable binding but are not immunogenic based on the
transgenic mouse study, is unsurprisingly larger, with 34 such combinations. Of these, NetMH-
CIIPan predicts 11 (32%) to be binding (at the 500nM cut-off, see S3B Table); this represents a
relatively low success rate for predicting binding but would be a high failure rate for predicting
immunogenicity as none of these pHLA are immunogenic. As for our analysis, 16 combinations
were informative (reached the Kullback-Leibler cut-off, S3C Table); of these, two (12.5%) were
incorrectly predicted to be immunogenic. This indicates that BIITE can successfully distinguish
between binding and immunogenicity. Another important benefit of BIITE compared to
NetMHCIIPan is that the results of BIITE are cohort-specific. That is, immunogenicity in two
cohorts (e.g. controllers and non-controllers) infected with the same pathogen can be compared
using BIITE. BIITE may find the same HLA:peptide combination to be immunogenic in one
cohort but not in another allowing an analysis of differing immune control between the cohorts
whereas NetMHCIIPan can only be used to determine whether a particular HLA:peptide combi-
nation is ever immunogenic. This is illustrated by our work on the PA dataset. In that dataset, we
could distinguish clinically between two groups which were marked by different ELISpot
response rates (group 2 i.e. “non-controllers” were poorly responsive with few positive ELISpots).
Since NetMHCIIPan does not use cohort data, it produces the same peptide:HLA binding predic-
tions (which in turn serve as a proxy for immunogenicity) for both groups and hence fails to cap-
ture the real differences in immunogenicity between the two groups. If we use transgenic mouse
data as the validation dataset for the poorly responsive group 2 then NetMHCIIPan reached an
AUC of 81.3%, compared to BIITE’s AUC of 68.8% (S4 Fig); however this analysis is misleading.
The cohort produces very few positive ELISpot responses and, accordingly, BIITE identifies very
few HLA:peptide combinations as being immunogenic compared to NetMHCIIPan. Arguably,
BIITE’s prediction of very few immunogenic peptide:HLA combinations compared to NetMH-
CIIPan is a more accurate representation of immunogenicity in this poorly responsive group.
Effect of HLA characteristics on model outcomes. Two concerns might arise regarding
the performance of our model: firstly, the model might prefer to assign higher immunogenicity
values to HLAs which are more common, as they might ‘hide’ less common but immunogenic
alleles in their hosts. Secondly, we want to ensure our analysis goes beyond a simple ‘counting’
algorithm, in which one considers immunogenic exactly those pHLA combinations for which
the highest percentage of HLA carriers produce positive ELISpots. In order to confirm that the
model is able to detect immunogenicity of peptide:HLA combinations where the HLA is rare
in the population, we plotted the predicted immunogenicity (posterior mode) of each pHLA
combination in the Burkholderia data set against the number of carriers of the HLA. While
having a low number of HLA carriers is restrictive in the sense that their posterior distributions
do not reach the Kullback-Leibler cut-off, those that do pass this requirement can be found to
be immunogenic by the algorithm (S5A Fig). Similarly, the percentage of positive ELISpots per
HLA allele is not strongly correlated with the posterior mode (S5B Fig); if we simply use the
count to predict immunogenicity then the AUC is very low (30%) suggesting our algorithm is
contributing far more than simply counting.
Validation on an HIV-1 dataset
As described in the methods, we also analysed the HLA-I dataset that was analysed in [10]. For
each peptide, HLAs were ranked by descending posterior mode provided by BIITE. To validate
the results, we compared the outcome to the LANL A-list [18] of best defined epitopes in HIV-
1. This is not ideal, since a peptide:HLA combination can be immunogenic without being fea-
tured on this A-list (i.e. we will tend to overestimate false positives); nevertheless, we used this
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list to determine lower bounds on the AUC. Both BIITE (AUC = 81%) and RATE
(AUC = 77%) performed well and were able to identify A-list peptide:HLA combinations (S6
Table). However, RATE’s ‘concise output file’ (S7 Table) included a number of peptide:HLA
combinations which are most likely not immunogenic but appear to be so due to linkage in the
HLA locus (highlighted in red in S7 Table. Strong linkage: p-value chi-square test< 2.210E-
16; linkage: p-value chi-square test< 0.01); this was not a problem with the BIITE algorithm.
This shows that BIITE is successful in handling possible confounding due to linkage disequilib-
rium between genetic loci, a recurring problem that is not dealt with by RATE.
Discussion
Determining the immunogenicity of peptide:HLA (pHLA) combinations is an important task
when studying correlates of immunity in infection, which in turn may inform vaccine design.
Different experimental and computational approaches have been used to establish this. The
experimental approaches include assessing the binding strength of the pHLA complex, in vitro
antigen presentation studies using CD4+ T cell clones, and HLA class II- transgenic mouse
models to mimic pathogen peptide expression in a human host. Each of these methods has
shortcomings. While binding (whether measured in binding assays or predicted) of a peptide
and immunogenicity of that peptide are correlated, binding is insufficient to guarantee immu-
nogenicity which entails other processes both in the antigen presentation pathways (such as
cleavage of protein into smaller peptides and the loading of peptides onto HLA-II molecules)
but also in the selection and expansion of the T cell clone(s) bearing the relevant TCR(s) in
vivo. More direct assays of immunogenicity such as CD4+ T cell cloning from bulk cultures
and assessment of peptide presentation using transfectants expressing individual HLA-II het-
erodimers are cumbersome and intractable for large-scale studies [19,20]. Transgenic mice are
good in vivomodels encompassing peptide processing and presenting pathways, but are
labour-intensive to develop and maintain. Furthermore, the overlap between which peptides
are immunogenic in humans and in mouse models is not perfect and seems to be highly depen-
dent on the choice of the effector cell [21]. As the mouse model incorporates a single human
HLA, it is also unsuitable to appreciate the effects of immunodominance, where different
HLAs may present different peptides simultaneously to the host’s immune system [22].
ELISpot assays use ex vivo PBMCs from exposed hosts to test peptidic immunogenicity. In
theory, this approach includes effects of peptide presentation pathway idiosyncrasies, binding
affinities between peptide and HLA, and immunodominance. As a trade-off however, we lose
the clarity of the experimental approaches where each HLA is studied independently, and it is
difficult to assess which peptide:HLA combinations cause the observed ELISpot outcomes.
Here, we have presented a Bayesian framework to perform this analysis. We have shown its
accuracy on both simulated and experimental data, and have determined the effect of sample
size. While higher sample sizes (100–200 subjects) would have yielded better results, the analy-
sis on a very limited dataset of 38 Burkholderia-sero-positive exposed subjects performed as
expected (AUC = 71%) from simulated data. A caveat should be given regarding the composi-
tion of the data set: analysis on data sets with high rates of positive ELISpots suffer from poor
identifiability. Nevertheless it is remarkable that with such a small dataset relatively high speci-
ficity and sensitivity could be achieved; while most algorithms for predicting immunogenicity
or binding require training datasets with hundreds of data points per HLA allele, we typically
have less than 10 data points per allele. Furthermore, unlike prediction algorithms, BIITE
explicitly uses cohort data, which makes it suitable to interrogate differences in immunogenic-
ity between patient groups responding differently to the same pathogen; this would be impossi-
ble for a binding prediction algorithm.
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This tool is available online as the R package BIITE and is, in essence, not ELISpot or HLA
class II-specific. In general, it can be used to attribute Boolean outcomes (such as therapeutic
success or disease progression) to allelic variation on multiple genes. As an example, we have
applied BIITE to an HLA class I ELISpot dataset (HIV-1). In general, to apply the algorithm to
a new problem it is necessary to consider carefully the source of the priors if these are to be
used; establish the length of the MH chain needed to obtain a representative sample of the pos-
terior distribution; and to consider issues of sample size and collinearity in the dataset.
It also allows for the addition of prior information ad libitum: we can envisage a scenario
where not only binding predictions (from NetMHCIIPan or other binding prediction algo-
rithms) but also binding data and transgenic mouse data are included in the prior. Of course,
conflicting binding information would result in different priors, and hence influence the out-
come of the algorithm. However, the effect of the prior is dependent on sample size; in a suit-
ably large dataset, the influence of the prior is outweighed by the likelihood factor.
Alternatively, confidence in the prior can be expressed in the prior itself: the more ‘flat’ a prior,
the less it will influence the posterior distribution.
In summary, we have developed a general approach which can be used for analysing com-
plex biological data. Whether or not a peptide:HLA combination is immunogenic involves a
number of interconnected immunological processes. To sidestep this complexity, reductionist
experimental approaches are often taken, e.g. in vitro stimulation with APCs expressing a sin-
gle HLA molecule; these approaches do not recapitulate a number of, potentially important,
biological details. We have developed an approach that allows us to use the most pertinent but
also most complex experimental data (ELISpot) and interrogate it to obtain accurate results.
Supporting Information
S1 Fig. Priors as used, depending on the predictions from NetMHCIIPan. A peptide:HLA
combination is considered to be a binder if the predicted binding affinity is below 500nM; the
prior for such a combination is the Beta distribution with mode 0.35 and SD 0.2. Peptide:HLA
combination with predicted binding affinity above 500nM have the Beta distribution with
mode 0.001 and SD 0.15 as prior.
(PNG)
S2 Fig. A comparison of the odds ratios of having a positive ELISpot (i.e. number of posi-
tive ELISpots/number of negative ELISpots for that peptide) in the original Burkholderia
dataset and the simulated data.
(PNG)
S3 Fig. Datasets with high ELISpot success rates are harder to analyse. (A) We ordered the
Burkholderia peptides based on their ELISpot success rates and considered subsets of this data-
set. We predict the AUCs to be negatively correlated with the success rate, i.e. the subsets to be
ordered as shown in (B) (subset 8 predicted to have the lowest AUC, subset 1 the highest). This
is indeed what we observe in (C).
(PNG)
S4 Fig. Comparison to NetMHCIIPan. (A) For the Burkholderia data. (B) for the Pseudomo-
nas data.
(PNG)
S5 Fig. The algorithm avoids the following pitfalls. (A) Posterior modes are not correlated
with the number of HLA carriers. (B) Posterior modes are not strongly correlated with the per-
centage of HLA carriers that produced a positive ELISpot. Data is taken from the analysis of
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the Burkholderia data set.
(PNG)
S1 Table. Count and frequency ofDRB1 and DQB1 alleles in the Burkholderia cohort.
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S2 Table. Count and frequency ofDRB1 and DQB1 alleles in the Pseudomonas cohort.
(DOCX)
S3 Table. Discordant results between binding assay and transgenic mouse models in Bur-
kholderia data set. (A) Peptide:MHC combinations which were found to be immunogenic in
the transgenic mouse model but did not bind in the binding assay, together with their predicted
binding IC50 from NetMHCIIPan, and the analysis of the posterior mode from our analysis.
The Kullback-Leibler divergence of the marginal posterior with respect to the uniform distribu-
tion is also indicated. (B,C) Peptide:MHC combinations which were not immunogenic in the
transgenic mouse assays but showed stable binding in the binding assay. Of these 34 combina-
tions, 11 were predicted to be binding (IC50 < 500 nM) by NetMHCIIPan (B). Marginal poste-
rior distributions from our model passed the Kullback-Leibler cut-off for 16/34 combinations
(C). Between these two tables, only five were found in common (highlighted in matching col-
ours).
(DOCX)
S4 Table. Example of an input file.
(CSV)
S5 Table. Count and frequency ofHLA-A, -B and -C alleles in the HIV-1 cohort.
(DOCX)
S6 Table. Analysis of the HIV-1 ELISpot dataset (BIITE).We analysed data from 32 peptides
(first column). These 32 peptides were the ones studied in [10] and were chosen because they
contain LANL HIV-1 A list epitopes that are restricted by HLAs which are abundant in the
cohort; this HLA is in the column ‘Restricting HLA (RATE)’. We also include the p value
reported by RATE for each peptide:HLA combination. In the next column, ‘Restricting HLA
(BIITE)’, we list the HLAs identified using BIITE that appear to elicit CD8+ T cell responses in
combination with the peptide. For these HLAs, we provide the number of carriers that pre-
sented a positive ELISpot response for the peptide in question and we count how in how many
responding carriers of the HLA this HLA had the highest posterior mode (‘# Carriers with pos-
itive ELISpot and highest rank’). We also show the posterior mode attributed to the peptide:
HLA combination. The last two columns document whether (and where) the peptide:HLA
combination was found in the LANL database.
(XLSX)
S7 Table. Analysis of the HIV-1 ELISpot dataset (RATE). Peptide:HLA combinations in the
‘concise results’ of RATE. Green highlighted alleles were detected by BIITE, while red
highlighted alleles are probably not immunogenic in combination with the peptide, but appear
to be so because of linkage disequilibrium.
(XLSX)
S8 Table. Example of an output file (pep_1 from the simulated data).HLAs are ranked from
highest to lowest posterior mode (‘Posterior Mode’) and we provide the number of carriers in
the cohort (‘# Carriers’) and the number of carriers who responded to the peptide. We also
show, per HLA, how many carriers have this HLA as their highest ranked HLA (‘# Carriers
with highest rank’); and how many carriers who responded to the peptide have this HLA as
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their highest ranked HLA (‘# Carriers with positive ELISpot and highest rank’). This last col-
umn can be interpreted as the number of positive ELISpots that are to be attributed to the spe-
cific HLA.
(XLSX)
S1 Text. Mathematical considerations. An explanation of the rationale and machinery behind
BIITE aimed at readers who do not have a background in Bayesian analysis.
(DOCX)
Acknowledgments
We have used the high performance cluster at Imperial College for this project. The authors
thank the Respiratory Biomedical Research Unit and patients at Royal Brompton and Harefield
National Health Service Foundation Trust funded by National Institute for Health Research.
We thank Professor Robert Wilson, Professor Diana Bilton and Dr. Michael Loebinger at
Royal Brompton Hospital London for their help recruiting the bronchiectasis/PA clinical
cohorts. We thank the staff members and patients at the Blood Transfusion Centre, Khon
Kaen Hospital, Khon Kaen, Thailand.
Author Contributions
Conceived and designed the experiments: LB DMA RJB BA PKO. Performed the experiments:
LB. Analyzed the data: LB BA. Contributed reagents/materials/analysis tools: KJQ CJR BM
JHR GL. Wrote the paper: LB BA DMA RJB.
References
1. Yewdell JW. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses.
Immunity. 2006; 25: 533–43. doi: 10.1016/j.immuni.2006.09.005 PMID: 17046682
2. Czerkinsky CC, Nilsson L-Å, Nygren H, Ouchterlony Ö, Tarkowski A. A solid-phase enzyme-linked
immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Meth-
ods. 1983; 65: 109–121. doi: 10.1016/0022-1759(83)90308-3 PMID: 6361139
3. Charron DJ, Lotteau V, Turmel P. Hybrid HLA-DC antigens provide molecular evidence for gene trans-
complementation. Nature. 1984; 312: 157–159. doi: 10.1038/312157a0 PMID: 6209579
4. Gjertsen HA, Lundin KE, Ronningen KS, Gaudernack G, Thorsby E. T cells recognizing an HLA-DQ
alpha beta heterodimer encoded in cis by the DR4DQw4 haplotype and in trans by DR4DQw8/
DRw8DQw4 heterozygous cells. Hum Immunol. 1991; 30: 226–232. PMID: 2055788
5. KwokWW, Schwarz D, Nepom BS, Hock RA, Thurtle PS, NepomGT. HLA-DQmolecules form alpha-
beta heterodimers of mixed allotype. J Immunol. 1988; 141: 3123–3127. PMID: 2844907
6. Altmann DM. HLA-DQ associations with autoimmune disease. Autoimmunity. 1992; 14: 79–83. PMID:
1299350
7. Lotteau V, Teyton L, Burroughs D, Charron D. A novel HLA class II molecule (DR alpha-DQ beta) cre-
ated by mismatched isotype pairing. Nature. 1987; 329: 339–41. doi: 10.1038/329339a0 PMID:
3306409
8. Lotteau V, Sands J, Teyton L, Turmel P, Charron D, Strominger JL. Modulation of HLA class II antigen
expression by transfection of sense and antisense DR alpha cDNA. J Exp Med. 1989; 169: 351–356.
PMID: 2462612
9. Karosiene E, Rasmussen M, Blicher T, Lund O, Buus S, Nielsen M. NetMHCIIpan-3.0, a common pan-
specific MHC class II prediction method including all three humanMHC class II isotypes, HLA-DR,
HLA-DP and HLA-DQ. Immunogenetics. 2013; 65: 711–24. doi: 10.1007/s00251-013-0720-y PMID:
23900783
10. Paul S, Dillon MBC, Lindestam Arlehamn CS, Huang H, Davis MM, McKinney DM, et al. A population
response analysis approach to assign class II HLA-epitope restrictions. J Immunol. American Associa-
tion of Immunologists; 2015; 194: 6164–76. doi: 10.4049/jimmunol.1403074
11. HastingsWK. Monte Carlo sampling methods using Markov chains and their applications. Biometrika.
1970; 57: 97.
Bayesian Immunogenicity Inference Tool for ELISpot
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004796 March 8, 2016 17 / 18
12. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation
for Statistical Computing; 2012.
13. Wickham H. ggplot2. Springer. 2009.
14. Reynolds C, Goudet A, Jenjaroen K, Sumonwiriya M, Rinchai D, Musson J, et al. T Cell Immunity to the
Alkyl Hydroperoxide Reductase of Burkholderia pseudomallei: A Correlate of Disease Outcome in
Acute Melioidosis. J Immunol. American Association of Immunologists; 2015; 194: 4814–24. doi: 10.
4049/jimmunol.1402862
15. Quigley KJ, Reynolds CJ, Goudet A, Raynsford EJ, Sergeant R, Quigley A, et al. Chronic Infection by
Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Mem-
brane Porin F. Am J Respir Crit Care Med. American Thoracic Society; 2015; 191: 1250–64. doi: 10.
1164/rccm.201411-1995OC
16. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell
responses to different HIV proteins have discordant associations with viral load. Nat Med. Nature Pub-
lishing Group; 2007; 13: 46–53. doi: 10.1038/nm1520
17. Nielsen M, Lund O, Buus S, Lundegaard C. MHC class II epitope predictive algorithms. Immunology.
2010; 130: 319–28. doi: 10.1111/j.1365-2567.2010.03268.x PMID: 20408898
18. Llano A, Williams A, Olvera A, Silva-Arrieta S, Brander C. Best-Characterized HIV-1 CTL Epitopes: The
2013 Update. In: Yusim K, Korber BTM, Brander C, Barouch D, Boer de R, Haynes BF, et al., editors.
HIV Molecular Immunology 2013. Los Alamos National Laboratory, Theoretical Biology and Biophys-
ics; 2013. pp. 3–25.
19. Wilkinson D, de Vries RR, Madrigal JA, Lock CB, Morgenstern JP, Trowsdale J, et al. Analysis of HLA-
DR glycoproteins by DNA-mediated gene transfer. Definition of DR2 beta gene products and antigen
presentation to T cell clones from leprosy patients. J Exp Med. 1988; 167: 1442–1458. PMID: 3128633
20. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G, et al. Myelin autoreactivity in
multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lympho-
cytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A. 1990; 87: 7968–
7972. PMID: 1700423
21. Kotturi MF, Assarsson E, Peters B, Grey H, Oseroff C, Pasquetto V, et al. Of mice and humans: how
good are HLA transgenic mice as a model of human immune responses? Immunome Res. 2009; 5: 3.
doi: 10.1186/1745-7580-5-3 PMID: 19534819
22. Deng H, Apple R, Clare-Salzler M, Trembleau S, Mathis D, Adorini L, et al. Determinant capture as a
possible mechanism of protection afforded by major histocompatibility complex class II molecules in
autoimmune disease. J Exp Med. 1993; 178: 1675–1680. PMID: 8228814
Bayesian Immunogenicity Inference Tool for ELISpot
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004796 March 8, 2016 18 / 18
